Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
4D Molecular Therapeutics, Inc. is a clinical-stage stage gene therapy company. The Company is focused on developing targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector), and pulmonology (aerosol vector). The Company's product candidates include 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and 4D-710 for the treatment of cystic fibrosis lung disease.

Number of employees : 83 people.
Sales per Business
20192020Delta
Gene Therapeutic Products6.99100%13.61100% +94.85%
USD in Million
Sales per region
2020
Switzerland12.9094.7%
Netherlands0.745.5%
United States-0.03-0.2%
USD in Million
Managers
Name Title Age Since
David H. Kirn, Dr. President, Chief Executive Officer & Director 58 2020
August J. Moretti Chief Financial Officer 69 2019
Melissa Kotterman, Dr. Vice President-Discovery & Engineering - 2013
Fred Kamal, Dr. Chief Operating & Technical Officer 57 -
Peter Francis, Dr. Chief Scientific Officer 51 2020
Robert Stephen Fishman, Dr. Chief Medical Officer 58 2020
David Schaffer, Dr. Independent Director 49 2013
Charles P. Theuer, Dr. Independent Director 56 2015
Jacob M. Chacko, Dr. Independent Director 41 2019
Susannah Gray Independent Director 59 2020
Members of the board
Name Title Age Since
John Milligan Executive Chairman 59 2020
David Schaffer, Dr. Independent Director 49 2013
David H. Kirn, Dr. President, Chief Executive Officer & Director 58 2020
Charles P. Theuer, Dr. Independent Director 56 2015
Jacob M. Chacko, Dr. Independent Director 41 2019
Susannah Gray Independent Director 59 2020
Nancy Miller-Rich Independent Director 61 2020
Shawn Cline Tomasello Independent Director 61 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,988,255 20,820,399 77.1% 0 0.0% 77.1%
Shareholders
NameEquities%
Viking Global Investors LP 3,937,914 14.6%
BVF Partners LP 2,005,862 7.43%
David H. Kirn 2,000,000 7.41%
David Schaffer 1,937,500 7.18%
Pfizer Inc. 1,666,658 6.18%
Janus Capital Management LLC 1,539,726 5.71%
Casdin Capital LLC 1,115,555 4.13%
Ridgeback Capital Management LP 1,100,000 4.08%
Fidelity Management & Research Co. LLC 1,037,265 3.84%
ArrowMark Colorado Holdings LLC 1,029,897 3.82%
Company contact information
4D Molecular Therapeutics, Inc.
5858 Horton Street
Suite 455
Emeryville, CA 94608

Phone : +1.510.505.2680
Web : http://www.4dmoleculartherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of 4D Molecular Therapeutics, Inc.
Sector Other Biotechnology & Medical Research